TNBC is a group of highly heterogeneous mixed breast cancers with seven subtypes, and endocrine and anti-HER2 treatment are ineffective treatment options for this cancer type (Lehmann et al., 2011). This evidence concerns the gene ERBB2 and breast carcinoma.